申请人:Metabolex, Inc.
公开号:US20140121246A1
公开(公告)日:2014-05-01
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
提供了GPR120激动剂。这些化合物对于治疗代谢性疾病,包括II型糖尿病和与血糖控制不良相关的疾病非常有用。